Navigation Links
Genomic Health Announces Year-End 2009 Financial Results
Date:2/3/2010

uarter of 2009, reflecting established payment patterns from payors with agreements to pay or contracts in place.

Total operating expenses for the fourth quarter 2009 were $39.9 million including cost of product revenues of $8.5 million, compared with total operating expenses of $33.9 million, including cost of product revenues of $7.3 million for the comparable period in 2008.  Included in operating expenses were non-cash charges of $4.3 million, including $2.6 million of stock-based compensation expense and $1.7 million of depreciation and amortization expenses in the fourth quarter of 2009, compared with non-cash charges of $3.8 million for the same period in 2008.

Total operating expenses for the year ended December 31, 2009 were $158.9 million including cost of product revenues of $32.6 million, compared with total operating expenses of $128.1 million, including cost of product revenues of $27.2 million for the comparable period in 2008.  Included in operating expenses were non-cash charges of $16.8 million, including stock-based compensation expense of $10.2 million and $6.6 million of depreciation and amortization expenses in the year ended December 31, 2009, compared with non-cash charges of $14.2 million for the same period in 2008.

2010 Outlook and Financial Guidance

"In 2010, we became a multi-product company with the launch of our colon cancer test;  
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Pa., Dec. 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... to fight cancers and infectious diseases, announced today that ... shares of its common stock and warrants to purchase ... which included the partial exercise of the underwriter,s overallotment ...
... -- The November 14, 2011, edition of ... Presence (VIP) as 4 stars ("would take it on ... Experiment (AEWE),s Spiral G at Fort Benning, GA, culminating ... and November 2011.  "It was a pleasure ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4VIPAAR's VIP Earns 4-star Technology Rating at AEWE's Spiral G 2
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ... efficiencies in healthcare information exchange, announced the release of its findings from its June ... (HHS) Secretary, WEDI shared survey results and recommendations , strongly encouraging ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bodybuilding.com, ... of nutritional supplements, has officially opened the polls for their eleventh annual ... following categories:, ,     Brand of the Year (BPI Sports) ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing ... from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to ... to share her cookbook Recipes from My Persian Kitchen with the world. , Since ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... South Korea, July 20 HepaHope Korea ... owned subsidiary, VASKA, a Berkeley-based producer of green, botanically-based ... successfully turned the first major commercial laundry plant in the United ... South San Francisco is the largest privately owned commercial laundry on ...
... , CARY, N.C., July 20 ... company focused on acquiring, developing and commercializing products primarily for ... Executive Vice President, Finance, and Chief Financial Officer, has been ... in the Small Public Business category. Award recipients were ...
... CARLSBAD, Calif., July 20 SynergEyes, Inc., ... a new advanced lens design for keratoconus patients. ClearKone(TM) ... the best features of the hybrid platform, providing superior ... design is optimized to vault the predominant irregularities of ...
... , BANNOCKBURN, Ill., July 20 Heart disease is ... it,s often not until the untimely passing of a celebrity from a ... the issue is brought to the forefront of Americans, health and wellness ... a recent survey(2) uncovered that only 14 percent of people would be ...
... Population older than 65 could reach 1.3 billion by 2040 ... people who are age 65 and older will double from ... 2040, says a new U.S. Census Bureau study. , The ... last year to 1.3 billion in 30 years. The unprecedented ...
... PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 The ... partnership to accelerate LLS,s pipeline of research projects entering late pre-clinical ... will begin with a selection of ten small molecule candidates, discovered ... of advancing into clinical trials in the shortest period of time. ...
Cached Medicine News:Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Elder Boom Will Be Felt Worldwide 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
... is a major upgrade of ... important physical and software changes ... and increase efficiency. The ACS:180 ... ACS:180. The productivity of the ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
... four channel Platelet Aggregation Profiler with three ... (Ristocetin cofactor), platelet aggregation and leukocyte aggregation. ... the evaluation and confirmation of Heparin Induced ... to be run simultaneously and independently. Select ...
... a four channel platelet aggregation profiler with ... von Willebrand assay (Ristocetin cofactor), platelet aggregation ... be used for the evaluation and confirmation ... allow four tests to be run simultaneously ...
Medicine Products: